Back to Oncology
Oncologyv2016Evidence-Based

GALAD Model for Hepatocellular Carcinoma (HCC)

Diagnoses HCC based on serum biomarkers in patients with chronic liver disease (CLD). The GALAD model combines Gender, Age, AFP-L3, AFP, and DCP (des-gamma-carboxy prothrombin) to provide superior diagnostic accuracy compared to individual biomarkers.

Clinical Input Parameters

years
Range: 18 — 100 years
ng/mL
Range: 0.1 — 100000 ng/mL
percentage
Range: 0 — 100 percentage
mAU/mL
Range: 1 — 100000 mAU/mL
Clinical Assessment
Awaiting Parameters
galad score
—score
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The GALAD Model for Hepatocellular Carcinoma (HCC) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within oncology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Z = -10.08 + 0.09 × age + 1.67 × sex + 2.34 × log₁₀(AFP) + 0.04 × AFP-L3 + 1.33 × log₁₀(DCP), where sex = 1 for males, 0 for females

Clinical Pearls & Practice Notes

  • Validated in patients with chronic liver disease at risk for HCC
  • Superior diagnostic accuracy compared to AFP, AFP-L3, or DCP alone (AUC 0.95 vs 0.88, 0.86, 0.87 respectively)
  • GALAD score ≥-0.63 suggests high probability of HCC with 85.6% sensitivity and 93.3% specificity
  • Performance superior to ultrasound alone for HCC detection (AUC 0.95 vs 0.82)
  • Particularly effective for early-stage (BCLC 0/A) HCC detection with AUC 0.92
  • Use lower limit of quantitation (LLOQ) when biomarker values are below detection limits
  • Model developed in cohorts with HCC prevalence 35-49%; performance may vary in different populations
  • Intended for patients with chronic liver disease including cirrhosis, hepatitis B, hepatitis C, NASH

Evidence & Literature Citations

  1. Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. Cancer Epidemiol Biomarkers Prev. 2014;23(1):144-53. doi: 10.1158/1055-9965.EPI-13-0870.
  2. Best J, Bechmann LP, Sowa JP, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2020;18(3):728-735.e4. doi: 10.1016/j.cgh.2019.08.012.
  3. Yang JD, Addissie BD, Mara KC, et al. GALAD Score for Hepatocellular Carcinoma Detection in Comparison with Liver Ultrasound and Proposal of GALADUS Score. Cancer Epidemiol Biomarkers Prev. 2019;28(3):531-538. doi: 10.1158/1055-9965.EPI-18-0281.

Score Interpretation Ranges

Low Risk-50 – -0.63 pts

Low probability of HCC

High Risk-0.63 – 50 pts

High probability of HCC

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.